Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1714027

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sipavibart
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the oral contribution by the Parliamentary Under Secretary of State at the Department of Health and Social Care during the debate on Covid-19: Response and Excess Deaths on Thursday 18 April 2024, Official Report, column 537, whether she has had recent discussions with (a) NICE and (b) the MHRA on their progress on reaching a decision on whether to recommend the use of Evusheld 2 to prevent covid-19.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	23829
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>The Department meets with the National Institute of Health and Care Excellence (NICE) regularly to discuss a range of issues, including access to medicines. The NICE has formally started its appraisal of AZD-3152, also known as sipavibart and referred to as Evusheld 2, ahead of the Medicines and Healthcare products Regulatory Agency’s (MHRA) decision on whether it should be given a United Kingdom marketing authorisation, and expects to invite stakeholder submissions in April 2024. Timelines for both the NICE’s guidance and licensing depend on data from the SUPERNOVA trial being available. AstraZeneca intends to submit clinical data to the NICE and the MHRA at the same time, with the aim that both organisations are able to reach decisions as close together as possible. If AZD-3152 is recommended as clinically and cost effective by the NICE, the National Health Service in England will be under a statutory requirement to fund AZD-3152 for eligible patients, in line with the NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 08:57:40 answering member 4044 label Biography information for Andrew Stephenson
tabling member	242 label Biography information for Sir Christopher Chope

1696697

registered interest
date	18/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Skin Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the effectiveness of drugs available within the NHS to treat (a) epidermolysis bullosa and (b) other inflammatory skin conditions.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	18966
answer	answer is ministerial correction date of answer 21/03/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes independent, evidence-based recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits.</p><p>Currently, there is one product licensed specifically for epidermolysis bullosa, Filsuvez gel, which contains birch bark extract. The NICE recommends birch bark extract as a clinically and cost effective use of NHS resources, and the NHS is legally required to fund it in line with the NICE’s recommendations. Other healthcare products are also used in the care of epidermolysis bullosa patients. There are a number of licensed and NICE recommended treatments for other inflammatory skin conditions that are now routinely available for NHS patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 21/03/2024 12:21:44 answering member 4044 label Biography information for Andrew Stephenson
tabling member	242 label Biography information for Sir Christopher Chope

1695752

registered interest
date	13/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Yellow Card Scheme: Medical Records
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, on what date work on digitally linking Medicines and Healthcare products Regulatory Authority Yellow Card information to NHS clinical records (a) began and (b) is expected to be completed.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	18345
answer	answer is ministerial correction date of answer 22/03/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) has been working with the National Health Service to explore approaches to facilitate digital linkage of Yellow Card information to clinical records, and to potentially enable faster access to information, where considered necessary for an assessment. Any such approach would be subject to strict information governance controls and prior consultation with stakeholder groups.</p><p>In 2020, the MHRA began delivery of a substantially enhanced Yellow Card platform under the SafetyConnect programme, aligned to the recommendations in Baroness Cumberlege’s Independent Medicines and Medical Devices Safety Review. The new infrastructure is designed with the intent of enabling connectivity to other systems, to facilitate the exchange of information. During that time the MHRA has engaged with the NHS around the evolving technical options for robust and secure connectivity and enhanced user journeys. The first step in these enhancements is use of the common NHS login capability within Yellow Card, which is expected to go live in 2024.</p><p>Deeper connectivity between systems will be subject to internal and external stakeholder engagement and substantial information governance controls, with elements completed over a phased and multi-year work plan.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/03/2024 10:33:41 answering member 4044 label Biography information for Andrew Stephenson previous answer version 24322 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
tabling member	242 label Biography information for Sir Christopher Chope

1692229

registered interest
date	27/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Christchurch Hospital
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when work on the Christchurch Hospital Macmillan Unit building project included in the New Hospital programme will begin.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	16052
answer	answer is ministerial correction date of answer 06/03/2024 answer text <p>As set out in the Trust's Full Business Case, it has been agreed that works at Christchurch Hospital, including those to enable the MacMillan palliative unit, are being funded and taken forward by the trust directly, in collaboration with the Macmillan Caring Locally Charity.</p><p> </p><p>The New Hospital Programme will be building a new hospital for Dorset Healthcare University NHS Foundation Trust at Alumhurst Road as supported by the local and regional health system.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 06/03/2024 12:46:08 answering member 4044 label Biography information for Andrew Stephenson previous answer version 20896 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
tabling member	242 label Biography information for Sir Christopher Chope

1686811

registered interest
date	01/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Staff
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what NHS England's policy is on hybrid working arrangements for (a) medical and (b) non-medical staff; and whether NHS England has made an assessment of the potential impact of working from home for up to (i) one, (ii) two, (iii) three and (iv) four days a week on levels of work productivity.
tabling member constituency	Christchurch
tabling member printed	Sir Christopher Chope
uin	12504
answer	answer is ministerial correction date of answer 21/02/2024 answer text <p>NHS England’s working from home policy, as of April 2024, will ask all colleagues with a contractual office base to spend, on average, at least 40% of their time working in-person. This will apply to both medical and non-medical staff.</p><p>A flexible work model will help the National Health Service to recruit and retain people more effectively, and is an important aspect of both the NHS People Promise and the NHS Long Term Workforce Plan. NHS England will continue to shape their ways of working based on what allows them to deliver high-quality services for all.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 21/02/2024 16:06:49 answering member 4044 label Biography information for Andrew Stephenson previous answer version 16018 answering member constituency Pendle answering member printed Andrew Stephenson answering member 4044 label Biography information for Andrew Stephenson
tabling member	242 label Biography information for Sir Christopher Chope